Product Information

SIGMA*FAST*™ DAB with Metal Enhancer

Tablet

D0426

Product Description

Diaminobenzidine (DAB) is used in many applications to visualize peroxidase activity.[1-6] The SIGMA*FAST*™ DAB with Metal Enhancer Tablet Sets have been developed for use in immunohistochemistry and dot blotting as a precipitating substrate for the localization of peroxidase activity. The DAB reaction has been enhanced by the addition of cobalt chloride. A distinctive, intense, dark blue to bluish black stain is produced that is stable and resistant to alcohol.

SIGMA*FAST*™ DAB with Metal Enhancer Tablet Sets require no additional ingredients or procedures to prepare an active substrate solution. One DAB/Cobalt tablet and one buffer/urea hydrogen peroxide tablet, when dissolved in 5 mL of ultrapure water, together produce 5 mL of ready-to-use substrate solution.

Peroxidase + 2 H_2O_2 → O_2 + 2 H_2O (pH 7.6)

O_2 + DAB/Co → insoluble, blue/black precipitate

Each SIGMA*FAST*™ DAB with Metal Enhancer Tablet Set produces the following solution when dissolved in 5 mL of H_2O:

- DAB: 0.5 mg/mL
- Cobalt Chloride: 0.2 mg/mL
- Urea Hydrogen Peroxide: 0.3 mg/mL
- Tris Buffer: 0.05 M
- Sodium Chloride: 0.15 M

This product has been used to study such systems as microglia slice cultures,[7] mouse model studies of disease[8,9] and of development,[10] cultured rat lung,[11] porcine molar teeth,[12] and embryos from zebrafish[13] and from *Haliotis* asinina.[14] Several theses[15-18] and dissertations[19-32] have cited use of product D0426 in their research protocols.

Storage/Stability

Store the tablets at –20 °C.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Components

DAB/Cobalt Tablets (Component Number D8552): 5 tablets (for 5SET) or 50 tablets (for 50SET)

Urea Hydrogen Peroxide Tablets (Component Number U4756): 5 tablets (for 5SET) or 50 tablets (for 50SET)

Reagents and Equipment Required but Not Provided

- Ultrapure water
- Pipette capable of delivering 5 mL
- Test Tubes
- Phosphate Buffered Saline (PBS), pH 7.4 (such as Cat. No. P3813), or:
- Tris-Buffered Saline (TBS), pH 8.0 (such as Cat. No. T6664)

Preparation Instructions

1. Remove the required number of DAB/Cobalt Tablets (Component Number D8552) and Urea Hydrogen Peroxide (Component Number U4756) Tablets from the freezer.
2. Allow the tablets to reach room temperature.
3. Open the DAB/Cobalt tablet package (silver foil) and the Buffer/Urea Hydrogen Peroxide tablet package (gold foil). Drop the tablets into an appropriate container. **Do not touch the tablets with your fingers.**
4. Add 5 mL of ultrapure water. Vortex until dissolved.

The SIGMA*FAST*™ DAB with Metal Enhancer Substrate Solution is now ready for use. For best results, the solution should be used immediately.

Procedure

1. Cover the tissue section with 0.2 to 0.5 mL of the SIGMA*FAST*™ DAB with Metal Enhancer Substrate Solution.
2. The DAB reaction may occur rapidly. Color development should be carefully monitored during the reaction to prevent overdevelopment and high backgrounds. Reactions may be stopped by gently washing the slide in water, PBS, or TBS.
3. Tissues stained with the SIGMA*FAST*™ DAB with Metal Enhancer Substrate Solution may be dehydrated with alcohol and mounted with traditional resinous mounting media.

Note: When finished, dispose of any remaining Substrate Solution in a proper manner.

Troubleshooting

Background is too high

1. Use a blocking step prior to the application of the primary antibody. Diluted normal serum (10% v/v) from the same species as the secondary antibody generally produces the best results.
2. Block endogenous peroxidase by flooding the slide with a solution of 4 parts methanol and 1 part 3% H_2O_2 solution.
3. Decrease the staining time.
4. Titer the conjugate to optimize working dilution.

No color develops or color is too faint

1. Adjust the concentration of the primary antibody.
2. Adjust the concentration of the secondary antibody.
3. Determine if the enzyme conjugate is active.
4. Consider using an amplifying system such as avidin-biotin or peroxidase anti-peroxidase.
5. Increase the staining time.
6. Determine if enzymatic treatment (unmasking) of the antigen is required prior to application of the primary antibody.

References

1. Nakane, P.K., and Pierce, G.B., Jr., *J. Histochem. Cytochem.*, **14(12)**, 929-931 (1966).
2. Trojanowski, J.Q. *et al*., *J. Histochem. Cytochem.*, **31,** 1217-1223 (1983).
3. DeJong, A.S.H. *et al*., *Histochem. J*., **17(10)**, 1119-1130 (1985).
4. Chu, N.M. *et al*., *J. Histochem. Cytochem*., **37(2)**, 257-263 (1989).
5. Merchenthaler, I. *et al*., "Silver Intensification in Immunocytochemistry", in *Techniques in Immunocytochemistry* (Bullock, G., and Petrusz, P., eds.). Academic Press Ltd. (San Diego, CA), pp. 217-252 (1989).
6. Hsu, S., and Soban, E., *J. Histochem. Cytochem*., **30(10)**, 1079-1082 (1982).
7. Colton, C.A. *et al*., "Slice Cultures for Study of Microglia", in *Protocols for Neural Cell Culture*, 3rd ed. (S. Federoff and A. Richardson, eds.). Humana Press (Totowa, NJ), pp. 29-37 (2001).
8. Fernando, G.J.P. *et al*., *Eur. J. Immunol*., **32(6)**, 1541-1549 (2002).
9. Wicki, A. *et al*., *Cancer Cell*, **9(4)**, 262-272 (2006).
10. Shi, D. *et al*., *Development*, **141(23)**, 4558-4568 (2014).
11. Jesudason, E.C. *et al*., *Am. J. Respir. Cell Mol. Biol*., **32(2)**, 118-127 (2005).
12. Traphagen, S.B. *et al*., *Biomaterials*, **33(21)**, 5287-5296 (2012).
13. Fraenkel, P.G. *et al*., *Blood*, **113(12)**, 2843-2850 (2009).
14. Koop, D. *et al*., *Dev. Biol*., **311(1)**, 200-212 (2007).
15. Orešković, Darko, "Razvoj perineuronskih mreža u sloju pod kortikalnom pločom mozga čovjeka" ("Development of perineuronal networks in the layer under the cortical plate of the human brain"). University of Zagreb, School of Medicine, M.Sc. thesis, p. 7 (2014).
16. Beckett, Matthew, "Toward understanding cranial sutures in zebrafish and chicken". Dalhousie University, M.Sc. thesis, pp. 138, 140, 142 (2015).
17. Zhong, Ziyun, "Understanding more about maternal vaccination and neonatal immunity to improve vaccine induced protection in early life". Imperial College London, M.Phil. thesis, p. 22 (2019).
18. Brown, Kirsty, "The intestinal microbiota contributes to the pathogenesis of Type 1 Diabetes in the non-obese diabetic mouse". University of British Columbia, M.Sc. thesis, p. 40 (2012).
19. Kaufmann, Christian, "Identification, Characterisation, and Function of Adipokinetic Hormones and Receptor in the African Malaria Mosquito, *Anopheles gambiae* (Diptera)". Université de Neuchâtel, Ph.D. dissertation, p. 109 (2007).
20. Dilgen, Jonathan E., "Basolateral Amygdala Stimulation Evokes Feed-Forward Inhibition in Medial Prefrontal Cortex". University of Maryland Baltimore, Ph.D. dissertation, p. 40 (2011).

21. Nollet, Mathieu, "Etude de l'implication fonctionnelle du système orexinergique dans les mécanismes physiopathogéniques de la dépression majeure" ("Study of the functional involvement of the orexinergic system in the physiopathogenic mechanisms of major depression"). Université François-Rabelais de Tours, Ph.D. dissertation, p. 214 (2011).
22. Loughran, Sinéad T., "Expression and role of the human anti-apoptotic *bfl-1* gene in Hodgkin's Lymphoma". Dublin City University, Ph.D. dissertation, p. 54 (2007).
23. McTaggart, James S., "Effects of Activating K_{ATP} Channel Mutations on Neuronal Function". University of Oxford, Ph.D. dissertation, p. 42 (2011).
24. Massa, Filippo Maria, "The crucial roles played by HNF1β during kidney development". Université René Descartes – Paris V, Ph.D. dissertation, p. 118 (2012).
25. Dalvi, Prasad S., "Molecular Mechanisms Involved in Insulin- and Leptin-mediated Regulation of Hypothalamic Proglucagon Gene Expression and Action of Glucagon-like Peptides on Hypothalamic Neuropeptides". University of Toronto, Ph.D. dissertation, p. 44 (2012).
26. Alves, Renato Manuel Pereira, "Studies of epithelial response to streptozotocin-induced hyperglycemia". Universidade de Aviero, Ph.D. dissertation, p. 69 (2013).
27. Roberts, Daniel Stephen, "The role of the proline rich homeodomain in the regulation of proliferation, survival and migration of breast cells". University of Birmingham, Ph.D. dissertation, p. 74 (2013).
28. Zhao, Hua, "Lysosomal cobalamin transport and its relevance to ageing and Alzheimer's disease". University of Wollongong, Ph.D. dissertation, p. 124 (2014).
29. Zhou, Hongkang, "The Essential Role of Stat3 in Bone Homeostasis and Mechanotransduction". Purdue University, Ph.D. dissertation, p. 39 (2014).
30. Alcaraz-Serrano, Maria del Amor, "ZFP36 proteins and mRNA targets in B cell malignancies". University of Westminster, Ph.D. dissertation, p. 60 (2015).
31. Heppleston, Audrey C., "Patterns and processes of digit number reduction". McGill University, Ph.D. dissertation, p. 104 (2010).
32. Boas, Vânia Filipa Esteves Vilas, "Targeting CXCR4 with immuno-modified iron oxide nanoparticles for cancer treatment with magnetically-induced hyperthermia: An *in vitro* approach". Universidade do Porto, Ph.D. dissertation, p. 116 (2017).
33. Mathew, Cynthia, "Disruption of XPO1-mediated Nuclear Export inhibits Respiratory Syncytial Virus (RSV) replication in cell culture: A novel antiviral therapeutic strategy against RSV". University of Canberra, Ph.D. dissertation, p. 57 (2019).
34. Soutar, Chloe Nicole, "Acute physiological effects of brain-generated 17β-estradiol in the rodent primary auditory cortex". Queen's University, Ph.D. dissertation, p. 44 (2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

D0426dat Rev 03/22 RBG,GCY,MAM